Products - Oesophageal cancer | Topic

Showing 15 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma (TA1160)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
3 June 2026
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
13 January 2027
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
10 February 2027
Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett’s oesophagus [ID6683]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 February 2027
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

Oesophageal cancer Products

Filter

Product type
1 selected

Guidance programme

Status

New and updated
1 selected

Showing 15 products

Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinoma (TA1160)

Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]

Capsule sponge tests for detection of Barrett's oesophagus and early-stage oesophageal cancer and surveillance of Barrett’s oesophagus [ID6683]

Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

Tislelizumab with chemotherapy for untreated unresectable or metastatic gastric or gastro-oesophageal junction cancer [ID6157]

Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]

Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

Bemarituzumab with chemotherapy for untreated inoperable HER2-negative advanced gastric or gastro-oesophageal junction cancer [ID6481]

Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]

Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]

Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672

Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723]

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

Serplulimab with chemotherapy for untreated PD-L1-positive unresectable advanced or recurrent oesophageal squamous cell cancer [GID-TA12038]

Oesophageal cancer Products

Filter

Product type1 selected

Guidance programme

Status

New and updated1 selected

Showing 15 products

Product type
1 selected

New and updated
1 selected